<p><strong>Nutriband Inc.</strong> (NASDAQ:NTRB) 的股東應該對過去一週股價上漲 27% 感到高興。但這並不能改變過去五年回報令人失望的事實。實際上，股價在這段時間內大幅下跌，下降了約 57%。那麼，最近的上漲是否足以恢復對該股票的信心？還不夠。然而，在最好的情況下（遠非 <em>fait accompli</em>），這種改善的表現可能會持續。</p>
<p>雖然過去五年對 Nutriband 的股東來説很艱難，但過去一週卻顯示出一些希望的跡象。那麼，讓我們看看長期的基本面，看看它們是否是負回報的驅動因素。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前入場。</p>
<p>Nutriband 在過去 12 個月內沒有盈利，因此其股價與每股收益（EPS）之間不太可能存在強相關性。可以説，收入是我們下一個最佳選擇。無盈利公司的股東通常希望看到強勁的收入增長。這是因為快速的收入增長可以很容易地推斷出利潤，通常是相當可觀的。</p>
<p>在過去五年中，Nutriband 的收入每年增長 16%。這比大多數虧損公司要好。相比之下，股價平均每年損失 9%——這相當令人失望。這可能意味着高期望已經被抑制，可能是因為投資者在關注底線。如果你認為公司能夠保持收入增長，你就必須考慮這裏可能存在機會。</p>
<p>公司的收入和盈利（隨着時間的推移）在下圖中展示（點擊查看具體數字）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/345353860-earnings-and-revenue-growth-1-dark-2/1767090025716?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/345353860-earnings-and-revenue-growth-1-dark-2/1767090025716"/></p>
<p>NasdaqCM:NTRB 收益和收入增長 2025 年 12 月 30 日</p>
<p>通過這份 <strong>免費</strong> 的資產負債表報告，更全面地瞭解 Nutriband 的財務健康狀況。</p>
<h2>不同的視角</h2>
<p>很高興看到 Nutriband 在過去 12 個月內為股東帶來了 33% 的總股東回報。值得注意的是，五年年化總股東回報損失為每年 9%，與近期的股價表現相比非常不利。長期的損失讓我們保持謹慎，但短期的總股東回報增長無疑暗示着更光明的未來。我發現從長期來看觀察股價作為商業表現的代理非常有趣。但要真正獲得洞察，我們還需要考慮其他信息。例如，投資風險的無處不在的陰影。<strong>我們已經識別出 Nutriband 的 4 個警告信號</strong>（至少有 2 個讓我們感到不安），理解這些信號應該是你投資過程的一部分。</p>
<p>當然，<strong>你可能會通過尋找其他地方找到一個絕佳的投資機會。</strong> 所以請查看這份 <strong>免費</strong> 的公司名單，我們預計這些公司將會增長盈利。</p>
<p><em>請注意，本文中引用的市場回報反映了目前在美國交易所上市股票的市場加權平均回報。</em></p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是人形的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨處可用。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>由 CiTech 贊助</p>

NTRB

<p>Nutriband Inc.（納斯達克代碼：NTRB）股票在過去一週上漲了 27%，但在過去五年中下跌了 57%。儘管近期有所上漲，但長期表現仍然令人失望，年化損失為 9%。在此期間，收入年增長率為 16%，好於許多未盈利公司。過去一年的總股東回報率為 33%，顯示出復甦的潛力。然而，由於與公司相關的風險已被識別，建議保持謹慎</p>

<p><strong>Nutriband Inc.</strong> (NASDAQ:NTRB) shareholders should be happy to see the share price up 27% in the last week. But that doesn't change the fact that the returns over the last half decade have been disappointing. In fact, the share price has declined rather badly, down some 57% in that time. So is the recent increase sufficient to restore confidence in the stock? Not yet. However, in the best case scenario (far from <em>fait accompli</em>), this improved performance might be sustained.</p>
<div class="lb-trans"><p><strong>Nutriband Inc.</strong> (NASDAQ:NTRB) 的股東應該對過去一週股價上漲 27% 感到高興。但這並不能改變過去五年回報令人失望的事實。實際上，股價在這段時間內大幅下跌，下降了約 57%。那麼，最近的上漲是否足以恢復對該股票的信心？還不夠。然而，在最好的情況下（遠非 <em>fait accompli</em>），這種改善的表現可能會持續。</p>
</div><p>While the last five years has been tough for Nutriband shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.</p>
<div class="lb-trans"><p>雖然過去五年對 Nutriband 的股東來説很艱難，但過去一週卻顯示出一些希望的跡象。那麼，讓我們看看長期的基本面，看看它們是否是負回報的驅動因素。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前入場。</p>
</div><p>Nutriband wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.</p>
<div class="lb-trans"><p>Nutriband 在過去 12 個月內沒有盈利，因此其股價與每股收益（EPS）之間不太可能存在強相關性。可以説，收入是我們下一個最佳選擇。無盈利公司的股東通常希望看到強勁的收入增長。這是因為快速的收入增長可以很容易地推斷出利潤，通常是相當可觀的。</p>
</div><p>In the last half decade, Nutriband saw its revenue increase by 16% per year. That's better than most loss-making companies. In contrast, the share price is has averaged a loss of 9% per year - that's quite disappointing. This could mean high expectations have been tempered, potentially because investors are looking to the bottom line. If you think the company can keep up its revenue growth, you'd have to consider the possibility that there's an opportunity here.</p>
<div class="lb-trans"><p>在過去五年中，Nutriband 的收入每年增長 16%。這比大多數虧損公司要好。相比之下，股價平均每年損失 9%——這相當令人失望。這可能意味着高期望已經被抑制，可能是因為投資者在關注底線。如果你認為公司能夠保持收入增長，你就必須考慮這裏可能存在機會。</p>
</div><p>The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).</p>
<div class="lb-trans"><p>公司的收入和盈利（隨着時間的推移）在下圖中展示（點擊查看具體數字）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/345353860-earnings-and-revenue-growth-1-dark-2/1767090025716" alt="" original-src="https://images.simplywall.st/asset/chart/345353860-earnings-and-revenue-growth-1-dark-2/1767090025716"/></p>
<p>NasdaqCM:NTRB Earnings and Revenue Growth December 30th 2025</p>
<div class="lb-trans"><p>NasdaqCM:NTRB 收益和收入增長 2025 年 12 月 30 日</p>
</div><p>Take a more thorough look at Nutriband's financial health with this <strong>free</strong> report on its balance sheet.</p>
<div class="lb-trans"><p>通過這份 <strong>免費</strong> 的資產負債表報告，更全面地瞭解 Nutriband 的財務健康狀況。</p>
</div><h2>A Different Perspective</h2>
<div class="lb-trans"><h2>不同的視角</h2>
</div><p>It's good to see that Nutriband has rewarded shareholders with a total shareholder return of 33% in the last twelve months. Notably the five-year annualised TSR loss of 9% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. <strong>We've identified 4 warning signs</strong> with Nutriband (at least 2 which don't sit too well with us) , and understanding them should be part of your investment process.</p>
<div class="lb-trans"><p>很高興看到 Nutriband 在過去 12 個月內為股東帶來了 33% 的總股東回報。值得注意的是，五年年化總股東回報損失為每年 9%，與近期的股價表現相比非常不利。長期的損失讓我們保持謹慎，但短期的總股東回報增長無疑暗示着更光明的未來。我發現從長期來看觀察股價作為商業表現的代理非常有趣。但要真正獲得洞察，我們還需要考慮其他信息。例如，投資風險的無處不在的陰影。<strong>我們已經識別出 Nutriband 的 4 個警告信號</strong>（至少有 2 個讓我們感到不安），理解這些信號應該是你投資過程的一部分。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking elsewhere.</strong> So take a peek at this <strong>free</strong> list of companies we expect will grow earnings.</p>
<div class="lb-trans"><p>當然，<strong>你可能會通過尋找其他地方找到一個絕佳的投資機會。</strong> 所以請查看這份 <strong>免費</strong> 的公司名單，我們預計這些公司將會增長盈利。</p>
</div><p><em>Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.</em></p>
<div class="lb-trans"><p><em>請注意，本文中引用的市場回報反映了目前在美國交易所上市股票的市場加權平均回報。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是人形的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨處可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 贊助</p>
</div>

Nutriband（NASDAQ:NTRB）的股東在過去一週內股價上漲了 27%，但在過去五年中仍然虧損